Manchikanti Laxmaiah, Knezevic Emilija, Knezevic Nebojsa Nick, Kaye Alan D, Atluri Sairam, Sanapati Mahendra R, Pampati Vidyasagar, Hirsch Joshua A
Pain Management Centers of America, Paducah, KY and Evansville, IN; Departments of Anesthesiology and Perioperative Medicine, University of Louisville, Louisville, KY; LSU Health Science Center, New Orleans, LA.
University of Illinois at Urbana-Champaign, College of Liberal Arts and Sciences, Champaign, IL.
Pain Physician. 2024 Dec;27(10):E995-E1032.
Recent research underscores the potential of intradiscal biologics, such as mesenchymal stem cells (MSCs), platelet-rich plasma (PRP), and alpha-2-macroglobulin, in promoting chondrogenesis within lumbar intervertebral discs as a treatment for discogenic low back pain. Studies indicate significant improvements in pain relief, physical function, and overall quality of life following these interventions.
This study aims to evaluate the effectiveness of intradiscal injections of MSCs and PRP in managing low back and lower extremity pain. A systematic review and meta-analysis were conducted to assess the outcomes of these treatments.
A systematic review and meta-analysis evaluating the efficacy of PRP and MSC injections for discogenic low back and lower extremity pain.
The review included literature from PubMed, Cochrane Library, the U.S. National Guideline Clearinghouse (NGC), prior systematic reviews, and reference lists, covering studies from 1966 to September 2024.
Randomized controlled trials (RCTs), observational studies, and case reports focusing on biologic injections into the disc were included.
Data were extracted and assessed for methodological quality. Evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria and summarized based on best evidence synthesis principles on a 1-to-5 scale.
The analysis included 8 RCTs (4 evaluating PRP, 5 evaluating MSCs) and 8 observational studies (4 assessing PRP, 4 assessing MSCs) for managing chronic low back pain. Evidence quality was deemed fair (Level III) with limited certainty and moderate recommendation strength based on qualitative and quantitative analyses.
Paucity of high-quality studies.
This systematic review and single-arm meta-analysis suggest that intradiscal injections of MSCs and PRP may be effective in managing discogenic low back pain, supported by Level III evidence.
近期研究强调了椎间盘内生物制剂的潜力,如间充质干细胞(MSCs)、富血小板血浆(PRP)和α-2-巨球蛋白,可促进腰椎间盘内软骨形成,作为治疗椎间盘源性下腰痛的方法。研究表明,这些干预措施后,疼痛缓解、身体功能及总体生活质量有显著改善。
本研究旨在评估椎间盘内注射间充质干细胞和富血小板血浆治疗下腰及下肢疼痛的有效性。进行了一项系统评价和荟萃分析以评估这些治疗的结果。
一项评估富血小板血浆和间充质干细胞注射治疗椎间盘源性下腰及下肢疼痛疗效的系统评价和荟萃分析。
该评价纳入了来自PubMed、Cochrane图书馆、美国国家指南资料库(NGC)、既往系统评价及参考文献列表的文献,涵盖1966年至2024年9月的研究。
纳入聚焦于向椎间盘内注射生物制剂的随机对照试验(RCTs)、观察性研究及病例报告。
提取数据并评估方法学质量。使用推荐分级的评估、制定与评价(GRADE)标准评估证据,并根据最佳证据综合原则在1至5级量表上进行总结。
分析纳入了8项RCTs(4项评估富血小板血浆,5项评估间充质干细胞)和8项观察性研究(4项评估富血小板血浆,4项评估间充质干细胞)用于治疗慢性下腰痛。基于定性和定量分析,证据质量被认为是中等(III级),确定性有限,推荐强度中等。
高质量研究匮乏。
本系统评价和单臂荟萃分析表明,椎间盘内注射间充质干细胞和富血小板血浆可能有效治疗椎间盘源性下腰痛,证据等级为III级。